motexafin-gadolinium and Lymphoma--B-Cell

motexafin-gadolinium has been researched along with Lymphoma--B-Cell* in 2 studies

Other Studies

2 other study(ies) available for motexafin-gadolinium and Lymphoma--B-Cell

ArticleYear
Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.
    Cancer research, 2005, May-01, Volume: 65, Issue:9

    To gain a better understanding of the mechanism of action of the metal cation-containing chemotherapeutic drug motexafin gadolinium (MGd), gene expression profiling analyses were conducted on plateau phase human lung cancer (A549) cell cultures treated with MGd. Drug treatment elicited a highly specific response that manifested in elevated levels of metallothionein isoform and zinc transporter 1 (ZnT1) transcripts. A549 cultures incubated with MGd in the presence of exogenous zinc acetate displayed synergistic increases in the levels of intracellular free zinc, metallothionein transcripts, inhibition of thioredoxin reductase activity, and cell death. Similar effects were observed in PC3 prostate cancer and Ramos B-cell lymphoma cell lines. Intracellular free zinc levels increased in response to treatment with MGd in the absence of exogenous zinc, indicating that MGd can mobilize bound intracellular zinc. These findings lead us to suggest that an important component of the anticancer activity of MGd is related to its ability to disrupt zinc metabolism and alter cellular availability of zinc. This class of compounds may provide insight into the development of novel cancer drugs targeting control of intracellular free zinc and the roles that zinc and other metal cations play in biochemical pathways relevant to cancer.

    Topics: Acetates; Antineoplastic Agents; Cadmium; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Lymphoma, B-Cell; Male; Metalloporphyrins; Neoplasms; Oxidation-Reduction; Prostatic Neoplasms; Thioctic Acid; Zinc; Zinc Acetate

2005
Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines.
    Cancer research, 2005, Dec-15, Volume: 65, Issue:24

    There is an emerging appreciation of the importance of zinc in regulating cancer cell growth and proliferation. Recently, we showed that the anticancer agent motexafin gadolinium (MGd) disrupted zinc metabolism in A549 lung cancer cells, leading, in the presence of exogenous zinc, to cell death. Here, we report the effect of MGd and exogenous zinc on intracellular levels of free zinc, oxidative stress, proliferation, and cell death in exponential phase human B-cell lymphoma and other hematologic cell lines. We find that increased levels of oxidative stress and intracellular free zinc precede and correlate with cell cycle arrest and apoptosis. To better understand the molecular basis of these cellular responses, gene expression profiling analyses were conducted on Ramos cell cultures treated with MGd and/or zinc acetate. Cultures treated with MGd or zinc acetate alone elicited transcriptional responses characterized by induction of metal response element-binding transcription factor-1 (MTF-1)-regulated and hypoxia-inducible transcription factor-1 (HIF-1)-regulated genes. Cultures cotreated with MGd and zinc acetate displayed further increases in the levels of MTF-1- and HIF-1-regulated transcripts as well as additional transcripts regulated by NF-E2-related transcription factor 2. These data provide insights into the molecular changes that accompany the disruption of intracellular zinc homeostasis and support a role for MGd in treatment of B-cell hematologic malignancies.

    Topics: Antineoplastic Agents; Apoptosis; DNA-Binding Proteins; Gene Expression Profiling; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphoma, B-Cell; Metalloporphyrins; NF-E2-Related Factor 2; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Response Elements; S Phase; Transcription Factor MTF-1; Transcription Factors; Tumor Cells, Cultured; Zinc

2005